Abstract: The present invention relates to a compound of the Formula: or a pharmaceutically acceptable salt thereof. The compound of the present invention inhibits Pol?. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Pol? activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Pol? activity is implicated.
Type:
Grant
Filed:
March 8, 2024
Date of Patent:
December 10, 2024
Assignee:
Breakpoint Therapeutics GmbH
Inventors:
Andrea Guerrero Corella, Stuart Robert Flanagan, Jonathan Hollick, Julien Gilbert Jacques Malassis, Matthew Raymond Smith, Ian Andrew Yule, Jonathan Mark Bentley
Abstract: The present invention relates to a compound of the Formula: and pharmaceutically salts thereof. The compound of the present invention inhibits Pol?. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Pol? activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Pol? activity is implicated.
Type:
Grant
Filed:
March 8, 2024
Date of Patent:
November 19, 2024
Assignee:
Breakpoint Therapeutics GmbH
Inventors:
Andrea Guerrero Corella, Stuart Robert Flanagan, Jonathan Hollick, Julien Gilbert Jacques Malassis, Matthew Raymond Smith, Ian Andrew Yule, Jonathan Mark Bentley